A generation of start-ups have failed to live up to the hype. Executives are now betting that more powerful tools will crack the complexities of human biology
Get 2 months free with an annual subscription at
was
€65.88
now
€54.
Research organisations are banking on technology to help improve the odds of approval
We need to learn from the mistakes we have made in the past
The experience of past tech revolutions suggests savvy incumbents might muddle through and even thrive
Development comes as tech groups bet on potential for AI to accelerate drug discovery and uncover new materials
Decent data for training AI models is becoming scarce and people are needed to make more of it
Warning from OpenAI’s Sam Altman and MIT paper puncture Wall Street’s enthusiasm
